Itb-med Llc

This study tested a new drug called TCD601 (siplizumab) in 33 kidney transplant patients to see if it could safely prevent organ rejection. The drug was compared to a standard treatment (ATG). The trial was stopped early, so we have limited information, but the goal was to find a…

This study tested a drug called siplizumab combined with donor bone marrow cells to help kidney transplant patients potentially stop taking anti-rejection drugs long-term. Only 4 people took part before the study was ended early. The goal was to find the best dose to safely allow…